Search

everythinglearnresearchcommunity

for

Search:↓

Amputation stump skin disease worsens life quality, especially in men during summer, and long prosthesis use increases fungal infection risk.

The rs231775 genetic variant is linked to a higher risk and severity of Alopecia Areata in males.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

The conclusion is that the risk of losing significance in meta-analysis results increases with smaller effects and more missing data, and using the median standard deviation for imputation is recommended.

COVID-19 doesn't make alopecia areata worse.

Model improves accuracy in predicting hair loss effects.

Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.

Probiotics significantly reduce the severity of atopic dermatitis.

High TSPEAR levels in colorectal cancer predict worse outcomes.

Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.

Oral and topical tranexamic acid effectively and safely improve melasma.

The VSCAPSI is a helpful method for evaluating the severity of scalp psoriasis.

Adults with Tatton-Brown-Rahman syndrome may have serious heart problems and need lifelong heart monitoring.

Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.

Unmarried individuals and those with diabetes have a poorer quality of life with alopecia areata.

Self-assessed hirsutism scores are not reliable for clinical diagnosis but may help in screening.

Topical rosuvastatin and melatonin creams significantly reduce psoriasis severity and are safe.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

Tacrolimus and corticosteroids can improve symptoms of Satoyoshi syndrome.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

The updated GRADE guidance advises considering context when interpreting variability in research results and introduces tools for assessing subgroup effects.

Patients with certain skin diseases are willing to spend significant time on treatment, indicating a high impact on their lives and a need for better treatments.

wAMD patients have higher oxidative stress, suggesting antioxidant treatment may help.

MITF+ melanoma patients are more likely to have multiple melanomas and unique skin patterns.

Squaric acid dibutylester can cause severe skin reactions in people with allergies.

Tinea corporis significantly reduces quality of life, so early detection and treatment are important.

The G allele of IFITM3 rs12252 is linked to more severe COVID-19.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

IMA and IMA/albumin levels don't predict alopecia areata severity.